Multimodal Liquid Biopsy Identifies 85% of Esophageal Adenocarcinoma Cases

A multimodal liquid biopsy identified cancer-associated molecular signals in 85% of patients with esophageal adenocarcinoma, according to a new study.

Liquid biopsy assays require a sharper focus on circulating tumor DNA biology and testing methods matched to clinical needs, according to Julia V. Burnier, PhD, MBA, Assistant Professor in the Gerald Bronfman Department of Oncology at McGill University in Montreal.

Dr. Burnier discussed tumor biology, treatment effects, and specimen collection influences on ctDNA measurements at the 2026 Association for Molecular Pathology (AMP) Annual Meeting & Expo in Seattle. Cell-free DNA measurements depend on tumor burden, cancer type, metastatic site, and DNA release mechanisms.

Apoptosis typically produces relatively short DNA fragments, whereas necrosis yields longer and more variable fragments. Cancer cells also actively release DNA through extracellular vesicles.

Chemotherapy increased cfDNA release in laboratory experiments involving lung and esophageal adenocarcinoma cell lines, with cisplatin-sensitive esophageal cancer cells releasing more DNA than resistant cells. Cisplatin exposure also shifted DNA fragmentation toward larger fragments.

“I think the clinical field has actually moved faster—which is rare—than the biology field,” Dr. Burnier said.

“So, we’re kind of catching up on understanding where these molecules come from, what they mean, and how they can help guide clinical decision-making,” she added.

Multimodal Detection in Esophageal Adenocarcinoma

Localized tumors often shed little ctDNA and lack recurrent hotspot mutations, prompting researchers to investigate multimodal testing approaches in esophageal adenocarcinoma. Investigators combined targeted next-generation sequencing, digital polymerase chain reaction, copy number alterations, and fragmentomics.

Combining these methods identified cancer-associated molecular signals in 39 of 46 patients, representing 85% of the group. Fragmentomics contributed the most unique detections to the analysis.

Using shallow whole-genome sequencing, investigators developed a classifier incorporating several cfDNA features. A simpler model using only fragment size and DNA end motifs achieved an area under the receiver operating characteristic curve of 0.82, with 76% sensitivity and 80% specificity.

Esophageal Adenocarcinoma Performance Models
Model Type AUC Sensitivity Specificity
Multimodal cfDNA Features 0.84 Not Reported Not Reported
Fragment Size and End Motifs 0.82 76% 80%
Prognostic Risk Model 0.81 83% 86%

HPV-Targeted Assays for Head and Neck Cancer

HPV-positive head and neck cancer carries a favorable prognosis, but standard treatments frequently cause substantial long-term morbidity. Dr. Burnier presented findings from an inexpensive, HPV-targeted digital PCR assay designed to monitor treatment response using blood and saliva.

HPV ctDNA was detected in 32 of 35 patients tested before treatment and 4 of 50 patients tested after treatment. Blood and saliva testing showed 93% concordance across 87 paired samples.

Three of four patients with detectable posttreatment ctDNA had residual disease or experienced recurrence. All 46 patients with undetectable posttreatment ctDNA showed no evidence of active disease during follow-up.

Questions About Liquid Biopsy Assays

What drives variations in circulating tumor DNA detection?

Detection levels depend directly on tumor burden, cancer type, metastatic site, and whether DNA release occurs via apoptosis or necrosis.

How does fragmentomics improve esophageal cancer detection?

Fragmentomics examines DNA fragmentation patterns, which contributed the most unique detections when combined with targeted sequencing and copy number alterations.

What does posttreatment HPV ctDNA indicate for head and neck cancer?

Patients with detectable HPV ctDNA after treatment frequently have residual disease or subsequent recurrence, while undetectable levels correlate with an absence of active disease.

Dr. Burnier earned her PhD in molecular and cell biology at McGill University, focusing on the molecular mechanisms of invasion and metastasis.

She then conducted postdoctoral research at McGill and at the Centre for Genomic Regulation in Barcelona, Spain, before studying cancer genomics in clinical trials at Princess Margaret Hospital in Toronto. Her laboratory at the RI-MUHC investigates circulating nucleic acids and tumor-derived extracellular vesicles in metastasis and the tumor microenvironment.

Can alternative samples replace cervical cancer screening?

“I am not here to say that PCR is better than NGS or that multimodal fragmentomics is better than mutational testing,” Dr. Burnier said.